In the age and gender analysis, the AUCs of the Vimentin/POU4F2 methylation panel for BC patients aged ≥ 50 years in the validation set were 0.947 (95% CI: 0.907–0.987) (Fig. 4C), with sensitivity and specificity of 86.96% and 96.59%, respectively (Tab. Here, VIM is linked to breast cancer.